glp-1 and kidneys agonists in the treatment of chronic kidney disease in type 2 diabetes obesity Glucagon-Like Peptide-1 Receptor Agonist Use
Description
The drug also causes food to linger in the stomach, which prolongs the feeling of fullness
Cortisol (stress hormone) and insulin resistance can both hinder weight loss
That positions GLP-1s as disease-modifying therapy, not just weight loss drugs
Huang, J
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J
The length of your treatment depends on the specific condition being addressed, the medication or therapy prescribed, and individual factors such as your age, overall health, and how you respond to treatment
